Allurion Technologies Holdings Inc. has announced findings from two new studies presented at the 2025 Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS). These studies reinforce the efficacy of the Allurion Program, which combines a procedure-less gastric balloon, AI-powered remote support, and real-time digital monitoring, in achieving metabolically healthy weight loss. The data, drawn from nearly 20,000 patients, demonstrate significant fat loss and preservation of muscle mass. Additionally, in one of the longest real-world studies of its kind, patients maintained, on average, 89% of the weight lost during balloon therapy over four years. These results contribute to Allurion's evidence base as the company prepares to complete its FDA submission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.